Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Apr;2(4):274-6.
doi: 10.18632/oncotarget.265.

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs

Ingeborg M M van Leeuwen  1 , Sonia Laín
Affiliations
Comment

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs

Ingeborg M M van Leeuwen et al. Oncotarget. 2011 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cartoon illustrating the concept of p53-based cyclotherapy
The p53 tumour suppressor is mutated in about 50% of human solid tumours in adults. Hence, administering a small-molecule p53 activator to patients bearing p53-mutant tumours would selectively activate p53 in normal tissues, inducing a mild reversible cell-cycle arrest. Subsequent treatment with conventional anticancer drugs should then kill proliferating cancer cells, whilst leaving normal cells untouched.
See this image and copyright information in PMC

Comment on

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
    1. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle. 2002;1:375–82. - PubMed
    1. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001;61:4301–5. - PubMed
    1. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–8. - PubMed
    1. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005;65:1918–24. - PubMed